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The overproduction of reactive oxygen species (ROS) has been linked to diseases 
and other pathologies.  As therapeutic agents, antioxidants have been tested and some 
shown to attenuate these diseases by relieving oxidative stress.  The May laboratory has 
previously developed a family of phenylaminoalkyl selenides and has demonstrated the 
antihypertensive and antioxidant properties of these compounds.  
 To further understand the antioxidant property of these selenide compounds, the 
two step mechanism of the reaction between the selenoxide form and glutathione was 
investigated by stopped-flow and mass spectrometry, leading to the detection and 
characterization of a novel thioselenurane intermediate.  Mass spectrometry studies 
supported the redox cycle of the selenide compounds as a straightforward cycle with no 
byproducts or side reactions and was the first evidence reported of a thioselenurane 
intermediate present in a reduction reaction of a selenoxide. 
The therapeutic potential of these compounds is further supported by cell and 
histological studies demonstrating their ability to alleviate the cardiotoxic effect of 
anthracyclines without affecting the anti-cancer property of the drugs.  Codosage of a 
phenylaminoethyl selenide with Doxorubicin decreased the infiltration of inflammation 
cells in the myocardium of mice.  Phenylaminoethyl selenides were also able to maintain 
the body weight of mice treated with Doxorubicin, compared to mice treated with 
Doxorubicin alone. 
To make the possibility of using Phenylaminoalkyl selenides as therapeutic agents 
or supplements with other agents, delivery of the compounds was investigated.  N acetyl 
xv 
 
phenylaminoethyl selenides were successfully encapsulated into poly(lactic-co-glycolic) 
(PLGA) nanoparticles using the nanoprecipitation technique.  An attempt was made to 
demonstrate the ability of these selenide- nanoparticles to reduce cellular oxidative stress 
caused by incubation with LPS.  Future studies are needed to optimize the loading of the 
selenide compounds into nanocarriers and to demonstrate the ability of the encapsulated 
drug to work as the free drug.  The long term goal of this research is to fully understand 
the potential of phenylaminoalkyl selenides as an efficient therapeutic agent for ailments 
derived from increased levels of ROS and a state of oxidative stress.   
 As a supplemental project funded by the National Science Foundation, the Center 
for Innovative Biomaterial Education and Research (CIBER) was created.  Enzymatically 
catalyzed reaction and polymerizations were investigated using Candida antarctica 
Lipase B (CALB).  Several CALB catalyzed Michael addition reactions were successful 
and yielded compounds that could be used as future reactants and monomers.  As an 
education requirement of the project a website was created to educate the public of the 
importance, sources and uses of biomaterials.  The website provides information for all 
levels of students and educators.  This center has allowed The Georgia Institute of 
Technology to form relationships and exchange programs with leading universities 






1.1 Reactive Oxygen Species:  Cellular Functions and Toxicity 
Life essentially developed in the absence of oxygen.  The advent of O2-evolving 
photosynthesis, including novel metabolic transformations, the generation of heat and 
light, and the ability to solubilize and detoxify compounds, lead to an increased rate of 
mutations and evolution.  Organisms were forced to either develop defenses against the 
toxic gas or to find anaerobic niches. The thought that oxygen is toxic to life forms for 
which it has become an essential component, is the “Oxygen Paradox”. 
The toxicity of oxygen gas is a result from its paramagnetic electronic structure, 
containing two unpaired electrons with the same spin state.  This feature makes the 
reaction of two oxygen molecules energetically unfavorable, as explained by the Pauli 
Exclusion Principle. This is overcome by the fact that electronic spins can be inverted by 
the interaction with nuclear spins.  Therefore, the reduction of oxygen takes place 
through the accepting of free electrons one at a time, in separate univalent electron 
transfers. Superoxide (O2
-), hydrogen peroxide (H2O2), hypochlorous acid (HOCl), 
peroxynitrite (ONOO-), and hydroxyl radical (HO˙) are intermediates produced either 
directly or secondarily through the reduction of oxygen.  These compounds belong to a 
class of radical and non-radical compounds known as reactive oxygen species (ROS) and 





Table 1.1.  Radical and Non-Radical Reactive Oxygen Species 
Radical Species Non-Radical Species 
O2
˙¯    superoxide radical 
HO˙   hydroxyl radical 
ROO˙   peroxyl radical 
RO˙   alkoxy radical 
HOO˙   hydroperoxyl radical 
 
H2O2  hydrogen peroxide 
HOCl  hypochlorous acid 
O3   ozone 
1O2  singlet oxygen 
 
Reactive oxidants are products of cellular metabolism, being produced by the 
mitochondrial electron-transport chain and oxygen-metabolizing enzymatic reactions 
such as xanthine oxidases, the cytochrome P450 system, NADPH oxidases, 
myeloperoxidases, and nitric oxide peroxidases.3, 4  Although high concentrations of ROS 
can be cytotoxic; the generation of these small molecules, within certain concentrations, 
is necessary to maintain homeostasis. At physiological concentrations, ROS, specifically 
H2O2, are known to play a role in cell signaling.  Intracellular redox environment has 
been linked to cell proliferation and differentiation, activation and inhibition of apoptosis, 
and the induction of necrosis.5-7  H2O2 plays a role in gene regulation, growth factor 
signaling, host defense, and wound detection and healing.3, 7-12 
Under normal physiological conditions, the production and elimination of reactive 
oxidants is maintained in balance by enzymes (catalase, glutathione peroxidase, 
thioredoxin, superoxide dismutase (SOD), etc.) and cellular small molecule antioxidants, 
including ascorbate and glutathione.  The natural production of ROS can be shifted by 
environmental stimuli, such as ionizing and UV radiation, and by the metabolism of 
drugs and xenobiotics, or by biochemical stimuli such as the over stimulation of 
deactivation of endogenous enzymes.  When this balance between cellular production and 
elimination of ROS is disrupted, a state of excess cellular oxidants occurs and is referred 




1.2. Oxidative Stress 
The state of oxidative stress causes various responses within a cell. Gene 
expression modulation, growth stimulation, temporary growth-arrest and apoptosis are all 
observed in stressed cells.  Necrosis, direct cell destruction, is the most extreme outcome 
of oxidative stress.13  ROS activate a number of nuclear transcription factors, cytokines, 
kinases and other immune system cells. These activations lead to increased inflammatory 
cytokine activation, and T cell apoptosis, resulting in a reduction in immune tolerance.14-
17  Due to these changes through redox signaling, oxidative stress has been found to be a 
cause of some diseases, and a secondary, contributing factor of others. It is known to play 
a role in various pathological phenomena including but not limited to cancer, 
hypertension, asthma, renal failure, atherosclerosis, Parkinson’s disease and HIV.3, 6, 13, 18-
23 
Oxidative stress has been shown to contribute to immune alterations and 
inflammatory conditions such as increased virulence.2,3,4  Studies by Beck et al. 
demonstrated that states of oxidative stress causes increased pathology, viral virulence 
and viral mutation.24  Vitamin E deficient and selenium deficient mice both showed 
increased susceptibility to the cardiotoxic effects of a myocarditic coxsackievirus.  In the 
same report, a benign strain of the virus, showing no cardiotoxic effects, caused heart 
damage when inoculated into vitamin E deficient mice.6 These studies lead to the 
conclusions that oxidative stress not only plays an important role in host resistance of 
viral infections, but also a role in the progression and pathology of the infection. 
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Evidence suggests that patients infected with the human immunodeficiency virus 
(HIV) are under chronic oxidative stress. Elevated serum levels of lipid peroxidation 
byproducts, increased oxygen consumption, and increased free radical production by 
neutrophils implies increased oxidative stress in asymptomatic HIV-infected and AIDS 
patients. HIV replication is increased under oxidative stress conditions in vitro. These 
effects of oxidants on viral replication have been demonstrated in studies in which 
antioxidants inhibited viral replication.13, 25-27 
 
1.3 Anti-oxidant Properties of Selenium 
Selenium (Se), discovered in 1817 by Jöns Jakob Berzelius, is an essential 
element and micronutrient.  The micronutrient enters the food chain via plants and 
vegetables through which it is taken up from the soil. Human consumption of Se comes 
primarily from shellfish, fish, and meat. Differences in soil selenium concentrations 
provide an explanation for greater Se deficiencies in some geographic areas than others. 
Although the average US resident meets the daily requirement of Se (55µg) with an 
average intake of 70-100µg/day, in many populations in Asia, Europe and parts of Africa 
the average daily intake is much lower than the normal nutritional requirement at less 
than 25µg/day.28, 29 Deficiency in dietary Se has been associated with diseases and 
aliments such as white muscle disease, heart disease, arthritis, cancer, and impaired 
immune response. 30-33 
In 1957, the biological importance of selenium was demonstrated by the work 
with Schwarz and Foliz and Patterson et al.34, 35  The discovery of selenoproteins and 
selenocysteine further established the necessity of the element and initiated the ever-
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expanding field of biological and medicinal selenium research.  The importance of 
selenium became clearer in 1973 when Rotruck et al. discovered its role in the formation 
of glutathione peroxidase, an enzyme that protects against oxidative injury. 36  Through 
the amino acid selenocysteine, Se is a component of at least 25 human selenoenzymes, 
playing a critical role in the redox center of several of these.  It has been proposed that 
this role in selenoproteins is the origin of the anti-oxidant and anticancer properties 
observed in selenium and organoselenium compounds.  In 1969, Shamberger and Frost 
reported the first suggestion of selenium’s protective effect against cancer.37  With the 
discovery of this property, small molecule selenium compounds increased in popularity 
for therapeutics for oxidative stress and its related diseases. 
 
1.4 Phenylaminoalkyl Selenides and Selenoxides 
Phenylaminoalkyl selenides (Figure1.1) were originally synthesized in the May 
laboratory as substrate analogs for Dopamine β-monooxygenase (DβM, 1.14.17.1), the 
key enzyme involved in catecholamine metabolism.  DβM catalyzes the ascorbate- 
 
Figure1.1.  Phenylaminoalkyl Selenides 
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dependent hydroxylation of dopamine to R-norepinephrine and is a target for modulating 
the peripheral adrenergic activity.  Experimental evidence demonstrated that 
phenylaminoalkyl selenides are oxidized by DβM to the corresponding selenoxides.  The 
inactivation of ascorbate-dependent DβM activity was achieved by the recycling of the 
selenoxide product back to the selenide form with the concomitant oxidation of reduced 
ascorbate.38-40 
The May laboratory later reported these compounds to exhibit dose-dependent 
antihypertensive properties in spontaneously hypertensive rats.39, 41  The compounds gain 
access to the peripheral adrenergic nerve terminal via a cocaine sensitive neuronal uptake 
mechanism, where they enter the adrenergic storage vesicles and inhibit the synthesis of 
norepinephrine.  This has further been demonstrated by the reduction of norepinephrine 
levels in cardiac tissue at levels that lower blood pressure.42, 43  More recently the 
antioxidant property of phenylaminoalkyl selenides was established in our laboratory, 
through the work of Woznichak et al. and De Silva et al.11, 44  Our lab showed that 
phenylaminoalkyl selenides react with cellular oxidants, peroxynitrite and hydrogen 
peroxide, in a stochiometric 1:1 molar ratio yielding the respective selenoxides.44  We 
also reported that the selenoxides are reduced back to the original selenide form via a 
redox reaction with cellular reductants.11  Antihypertensive and antioxidant properties 
make phenylaminoethyl selenides very attractive organoselenium compounds for 
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CHAPTER 2  
IDENTIFICATION OF A THIOSELENURANE INTERMEDIATE IN 
THE REACTION BETWEEN PHENYLAMINOALKYL 
SELENOXIDES AND GLUTATHIONE 
 
2.1 Introduction 
In epidemiological studies, a low concentration of selenium in plasma has been 
identified as a risk factor for many of the same diseases associated with oxidative stress.1-
6  A number of investigators have suggested that organoselenium compounds capable of   
propagating a selenium redox cycle might supplement natural cellular defenses against 
oxidants, and indeed, several organoselenium compounds with antioxidant, anti-
hypertensive or anti-cancer activity have been reported.7-25 
As discussed in chapter 1, a family of novel phenylaminoalkyl selenides has been 
developed in our laboratory.  We have shown that these compounds are potent 
antioxidants, reacting rapidly with a variety of metabolic oxidants (ONOO-, H2O2, etc.), 
and that they are readily taken up into cells and have low toxicity in vivo (mice and 
rats).7, 20, 21  Moreover, the selenoxide products generated from the antioxidant activity of 
these selenides are readily recycled back to the selenide form by cellular reductants such 
as glutathione (GSH).9, 20, 22-24, 26, 27  We have also shown that as a consequence of this 
selenium redox cycling, our compounds protect DNA against damage caused by the 









Among the proposed selenium intermediates in the oxidation-reduction reactions 
of organoselenium compounds are species such as selenenic and seleninic acids, 
selenones, spirodioxaselenanonanes and thiolseleninates, Table 1.1.12, 18, 25, 28-31  Thus, for 
example, evidence has been reported for formation of a thiolseleninate intermediate in the 
reactions between Ebselen oxide and certain thiols30, 32, a spirodioxaselenanonane 
intermediate in the reaction between di(3-hydroxypropyl) selenide and tert-butyl 
hydroperoxide12, and a thioselenurane intermediate for the reaction between benzenethiol 
and a substituted phenyl benzyl selenoxide.30  The reactivity and instability of some tetra-
coordinate selenium compounds, coupled with fast reaction rates for the reactions of 
organoselenium compounds with oxidants or with reducing agents such as thiols, have 
made it difficult to clearly characterize thioselenurane-like intermediates.28, 32-34  We now 
report evidence from stopped-flow kinetic and mass spectrometry experiments that the 
oxidation-reduction reaction between phenylaminoalkyl selenoxides and glutathione 


















2.2 METHODS AND MATERIALS 
2.2.1  Materials  All chemicals and solvents were used without further purification as 
received unless otherwise noted.  Reduced and oxidized glutathione (GSH and GSSG), 
30% hydrogen peroxide solution (H2O2) and manganese dioxide were obtained from 
Sigma Chemical Co. (St. Louis, MO).  Deuterated solvents were purchased from 
Cambridge Isotope Laboratories, Inc. (Andover, MA).  All other chemicals were 
purchased from standard commercial sources and were of the highest grade available.  
Allsphere C8 HPLC column was obtained from Alltech (Deerfield, IL). 
2.2.2  Synthesis of Phenylaminoethyl Selenides  PAESe and PAES were synthesized 
and characterized by Dr. James E. Colbert as previously reported.21  
Fluorophenylaminoethyl selenide (FPAESe) and chlorophenylaminoethyl selenide 
(ClPAESe) were prepared and characterized by Dr. Michelle M. Woznichak as reported 
in the literature.20 
2.2.3  Synthesis of Phenylaminoalkyl Selenoxides  Phenylaminoalkyl selenoxides were 
synthesized   as previously described.24, 27  Selenides were dissolved in H2O and reacted 
with 30% H2O2 in a 1:2 molar ratio. The reaction was monitored by HPLC (UV detection 
at 266nm, Alltech Allsphere Octyl (C8) 5u, 250mmx 4.6 mm; mobile phase: 20% 
acetonitrile, 0.1% TFA, flow rate 1mL/min).  The completed reaction was quenched with 
the addition of MnO2, filtered and lyophilized overnight. 
2.2.4  Spectrophotometric Experiments  The reduction of selenoxides, FPAESeO and 
ClPAESeO with GSH was investigated on a Hewlett Packard 8453 diode-array 




Extinction coefficients were determined by taking the slope of the absorbance of multiple 
concentrations of selenide or selenoxide.   
2.2.5  Stopped-flow Kinetic Experiments  Stopped-flow experiments were carried out 
on an OLIS UV/VIS RSM 1000 rapid-scanning spectrophotometer (Bogart, GA, USA) 
with 3.16 entrance and exit slits, 600 lines/mm gratings and a Xenon 75 Watt lamp.  
Syringes and flow cell were thermostated by a Fisher Scientific Isotemp 3016 circulating 
water bath.  A 0.75mL stop volume was used for all experiments.  Reactant solutions and 
buffers were made fresh before each experiment and kept on ice during the course of the 
experiment.  Stock solutions and dilutions of GSH and selenoxides were prepared in 
buffer.  Stopped-flow syringes and flow cell were rinsed thoroughly with distilled water 
and buffer before collection of data.  Syringes were filled with GSH (100-1600µM) and 
selenoxides (50-1600µM) in 100mM buffers ranging in pH from 1.7 to 9.0.  Loaded 
syringes were allowed to set for 10 minutes in order equilibrate with the temperature of 
the water in the syringe chamber.  Absorbance data were collected from 240-300nm for 3 
to 500 seconds.  Wavelengths and collection times were adjusted according to 
concentration, pH and temperature. 
2.2.5.1  Olis Global Works Software  Olis GlobalWorks software was used to fit the 
stopped-flow data with a three species A→B→C fast/slow kinetic model.  The software 
uses Singular Value Decomposition (SVD) and Matrix Exponentiation to analyze the 
three-dimensional data (absorbance data collected with respect to wavelength and 
time).35-37 SVD determines the number of species present in the reaction, while Matrix 
Exponentiation global fitting is used to fit the data with a chosen kinetic model.  SVD 




patterns.  The varying patterns are referred to as eigenvectors, because they represent an 
accumulation of data rather than one specific piece of information.  The number of 
eigenvectors and how they change as a function of time is used to determine the number 
of components in the reaction and the kinetic trace for these components. 
2.2.6  Mass Spectroscopy  Positive mode ion electrospray ionization mass spectroscopy 
(ESI-MS) and tandem ESI mass spectrometry (ESI-MS/MS) experiments were performed 
on a triple quadrupole tandem mass spectrometer (Micromass Quattro LC) coupled with 
an Agilent 1100 binary HPLC system.  Source and desolvation temperatures were 
maintained at 100ºC and150ºC respectively for all experiments.   
2.2.6.1  Flow Injection Experiments  ESI-MS spectra were acquired by 10µL injections 
of selenoxide solution via an Agilent 1100 autosampler (pump flow rate of 200µL 
methanol/min) into a continuous stream of a GSH generated by a KD Scientific syringe 
pump (flow rate of 50µL/min).  The two solutions were mixed in a tee located as close to 
the mass spectrometer source as possible and the LC and syringe pump flow rates, 
concentration of GSH and selenoxide, and injection volume of selenoxide were all 
optimized.  Optimal voltages for ESI-MS were cone voltage (CV) 20V and capillary 
energy (CE) 3.5V.  
2.2.6.2  Tandem Mass Spectrometry  For tandem mass spectrometry (ESI-MS/MS) 
experiments the reactants were diluted in 50/50 water/acetonitrile with 0.1% formic acid.  
The same setup used in the ESI-MS experiments was used except 100µL injections of 
FPAESeO were made at a flow rate of 200 µL/min into a stream of GSH (flow rate 




fragmentation of the precursor ion m/z 543.  Voltages were optimized to be CV 55V and 
CE 25V.   
2.2.7  77Se NMR Experiments  
77Se nuclear magnetic resonance (NMR) spectroscopy 
experiments were performed on a Bruker DMX 400 NMR spectrometer. 
Tetramethylsilane (TMS) and dimethyl selenide were used as standards for 1H, 13C and 
77Se experiments and methanol was used for temperature calibration.  Reactions were 
carried out at temperatures ranging from -45 to 3°C.  Samples were prepared in 80/20 
deuterated methanol/ deuterated water and were kept on ice until analysis.  Deuterated 
acetic acid was used in samples where the pH was lowered.  A reaction setup that 
allowed for the constant formation of the intermediate was used.  Selenoxide solution was 
placed in an NMR tube and tubing (O.D. 1/8”, I.D. 1/16”) cut at a slant was inserted into 
the NMR tube until it almost touched the bottom of the tube.  The tubing allowed for the 
continuous addition of GSH into the FPAESeO sample via a syringe pump (flow rate 




2.3 RESULTS AND DISCUSSION 
2.3.1 Stopped-flow Experiments 
Stopped-flow experiments were conducted to determine whether or not a reaction 
intermediate is kinetically detectable for the reaction between fluorophenylaminoethyl 
and chlorophenylaminoethyl selenoxides and glutathione.  We have previously shown 
that this is a facile process and the stoichiometry for the overall reaction is one molecule 
of selenoxide reacting with two molecules of GSH to produce one selenide molecule plus 
one molecule of GSSG 24.  Supplemental data for stopped-flow experiments was gathered 
on a Hewlett Packard HP 8453 diode-array spectrophotometer, including expected 
changes in absorbance for the conversion from selenoxide to selenide (Figure 2.3) and 
extinction coefficients for selenides and selenoxides.  
 
 






Figure 2.3.  ClPAESeO (Black) and ClPAESe (Red) UV Absorbance 
 
Figure 2.4A illustrates typical absorbance changes recorded by the 
photomultiplier tube detector of the stopped-flow instrument over a 2.6 sec reaction 
period for the reaction of ClPAESeO with GSH.  The overall increase in absorbance in 
the 262nm region reflects formation of the selenide product, which has a greater 
extinction coefficient than the selenoxide at this wavelength (5288 M-1cm-1 vs. 4134 M-
1cm-1).  Control experiments confirmed that, as expected, no reaction is detectable when 
either GSSG and ClPAESeO or GSH and ClPAESe are mixed in the stopped-flow 
instrument.   
Figure 2.4B illustrates the results obtained when Olis GlobalWorks software was 
used to fit the raw data to a three species A → B → C fast/slow kinetic model.  This 
software uses Singular Value Decomposition (SVD) and Matrix Exponentiation to 
analyze the three-dimensional stopped-flow data (absorbance data collected with respect 
to wavelength and time). 35-37  Traces A and C are kinetic traces of the eigenvectors for 
the selenoxide substrate and the selenide product, respectively.  Formation, buildup and 
decomposition of a reaction intermediate are clearly evident as seen in the kinetic trace of 





Figure 2.4.  Stopped-flow spectra of the oxidation of glutathione by ClPAESeO. A) Raw absorbance data collected. B) GlobalWorks 
calculated (a) decrease of reactant selenoxide, (b) build-up and decomposition of the intermediate, and (c) increase of selenide 






Traces A and C are kinetic traces of the eigenvectors for the selenoxide substrate and the 
selenide product, respectively.  Formation, buildup and decomposition of a reaction 
intermediate are clearly evident as seen in the kinetic trace of eigenvector B.  Traces D 
and E are the sum of the eigenvector absorbances and the predicted results from the 
chosen model, respectively.  The excellent overlay of these traces and the equal 
randomness of the residuals (Figure 2.5) indicate that the kinetic model chosen is 
appropriate for the data.  Several two and three species models within Olis GlobalWorks 
software were tried, but based on the criteria discussed by Matheson, Parkhurst, and 
DeSa 35-37, none of the other models gave a good fit to the kinetic data set.  The second 
order rate constants calculated by Olis GlobalWorks for intermediate formation and 
decomposition at 10˚C were 4010 and 1120 M-1s-1 for FPAESeO (pH 7.0), and 5844 and 
1412 M-1s-1 for ClPAESeO (pH 7.5), respectively. 
 
Figure 2.5.  GlobalWorks residuals from oxidation of GSH with ClPAESeO. 
 
 
A reaction scheme consistent with these kinetic results is shown in Figure 2.6.  As 
shown, initial attack of a thiolate on a selenoxide moiety should generate a thioselenurane 




products, GSSG and selenide.  This reaction scheme is consistent with our stoichiometry 
results and the stopped-flow kinetic data indicate that the rate of formation of the 
intermediate is approximately 4-fold faster than its decomposition under our reaction 
conditions.  We therefore reasoned that it might be possible to obtain direct structural 










Se NMR  
Kumakura et al .34 and Haenen et al. 38 were unsuccessful in attempts to use NMR 
to visualize and characterize thioselenurane-like intermediates in the reaction between 
selenoxides and thiols.  Nevertheless, we attempted to detect the putative thioselenurane 
intermediate through the use of 77Se, 1H, and 13C NMR.  These experiments were carried 




setup designed to allow for constant formation of the intermediate, thereby increasing the 
likelihood of its detection by NMR.  As demonstrated in Figure 2.7, we observed a 
kinetic decrease in selenoxide (871.16 ppm) and increase in selenide (254.66 ppm), but 
were unable to detect any other selenium-containing species.  Our results are therefore 
consistent with the previous reports by Kumakura  et al.34, Glass et al.39, and Haenen et 
al.
38who were also unable to detect intermediates in reactions between selenoxides and 





Figure 2.7.    Stacked 77Se NMR showing decrease of selenoxide and increase of 





2.3.3  Tandem Mass Spectrometry  
An alternative approach is exemplified by the work of Santos 40, Greip-Raming et 
al. 41, and many others who have successfully used ESI-MS and ESI-MS/MS for the 
detection of short-lived reaction intermediates in solution.  Among the advantages of this 
approach are the mild formation of ions in ESI and the high sensitivity of mass 
spectrometry 40, 42-44. Generally, intermediates have been studied using ESI-MS through 
one of two major techniques; the first of these is “ion-fishing”, in which intermediates are 
transferred to the gas phase and then trapped with a charge-labeled compound 41, 45, 46.  
The second technique entails the mixing of two or more reactants via a microreactor 
before the ions enter the ionization source; this latter technique was utilized here to 
monitor the reaction between selenoxides and GSH 46, 47.  Injections of selenoxide were 
made, via a liquid chromatography pump, into a continuous stream of GSH, created by a 
syringe pump, immediately before entering the ESI source. 
An additional aspect of ESI-MS is that certain elements can be identified based on their 
isotope patterns.  Selenium has six naturally occurring isotopes, 74Se 0.89%, 76Se 9.37%, 
77Se 7.63%, 78Se 23.77%, 80Se 49.61% and 82Se 8.73%; the most abundant of these is 
80Se.  This creates a very distinct isotopic pattern and makes any selenium-containing 
species easily distinguishable in the mass spectrum of a complex mixture.  Figure 2.8 
shows a series of ESI-MS spectra obtained for the reaction between ClPAESeO and GSH 
(Panels A, B and C) and between FPAESeO and GSH (Panels D, E and F).  The spectrum 
from 300 to 620 m/z for the ClPAESeO reaction is shown in panel A.  Peaks for GSH 
([M+H]+ m/z 307.9), GSSG ([M+H]+ m/z 614.9), and proton-bound dimers of selenium-




arising from a selenium species is observed at m/z 559.  This peak was not observed 
when either GSH or the selenoxide was omitted from the reactions, demonstrating that 
the formation of the ion at m/z 559 only occurs when both selenoxide and GSH are 
present. Similar results were obtained for the reaction between FPAESeO and GSH 
(Panels D, E and F), with a new selenium-containing peak appearing at m/z 43.  
It is evident by the isotopic pattern of the intermediate m/z 559 and m/z 543 ions 
(Panels B and E) that selenium is indeed present in the intermediate.   The comparison of 
the intermediate peaks with the theoretical isotope modeling (MassLynx NT) of the 
proposed intermediates is shown in panels B and C (ClPAESeO reaction intermediate) 
and panels E and F (FPAESeO reaction intermediate).  As seen in these panels, the 
masses and isotope pattern of the experimental and theoretical spectra are in excellent 
agreement.  These results provide initial evidence that the intermediate formed in the 
reaction of the phenylaminoalkyl selenoxides and GSH is indeed a selenium-containing 
species, which corresponds to the molecular mass of the thioselenurane intermediate 





Figure 2.8.  Mass spectroscopy of the reaction between phenylaminoethyl selenides and 
GSH.  (A) ESI (+) mass spectrum of the reaction between ClPAESeO and GSH.  (B) ESI 
(+) experimental mass spectrum for 559 m/z.  (C) Theoretical isotope model of 
thioselenurane intermediate ([M+H]+ C18H28ClN4O7SSe).  (D) ESI (+) mass spectrum of 
the reaction between FPAESeO and GSH. (E) ESI (+) experimental mass spectrum for 





Flow injection ESI-MS/MS experiments were carried out in order to obtain 
further characterization of the intermediate.  As seen in Figure 2.9, product ion scans of 
the thioselenurane intermediate present in the reaction between FPAESe and GSH (m/z 
543 cation) resulted in daughter ions of glutathione ([M+H]+, m/z 308) and selenoxide 
([M+H]+, FPAESeO m/z 236).  The observed daughter ions agree with the expected 
fragmentation pathways for the thioselenurane intermediate (Figure 2.10).  The two 
observed peaks of equal intensity observed in Figure 2.8 can be explained by the ability 
of both fragments to stabilize the charge and Stevenson’s rule, which states that the 
charge will remain on the fragment with the lower ionization energy 48 
The results reported here provide, to our knowledge, the first evidence for the 
intermediacy of a thioselenurane species in the reaction of a thiol with a selenoxide.  As 
evidenced by stopped-flow kinetic data, a rapid and stoichiometric initial reaction of 
either fluoro- or chlorophenylaminoethyl selenoxide with GSH generates a kinetically-
detectable intermediate, and a subsequent slower reaction of this intermediate with a 
second molecule of GSH produces the final selenide and GSSG products.  Flow injection 
ESI-MS experiments confirmed that the reaction intermediate is indeed a selenium-
containing species with a molecular mass and selenium isotopic pattern corresponding to 
that of the thioselenurane that would be produced by attack of GSH on a 
phenylaminoalkyl selenoxide.  Final structural characterization of the thioselenurane 














Figure 2.10.  Fragmentation pathways of the thioselenurane intermediate showing 






Over the years, a number of investigators have proposed the formation of 
intermediates in the reaction of selenoxides with reducing agents.  In 1978, Kice and Lee 
28 detected the presence of an intermediate via UV absorption in the reaction between 
benzeneseleninic acid and 1-butanethiol or 2-methyl-2-propanethiol.  Because of 
instability of this intermediate, the authors were unable to obtain structural information 
confirming its structure.  However, they suggested it might be either a thioseleninate or a 
thioselenurane, with the more likely possibility being the former.  Kumar et al. 30 
proposed the formation of a thioselenurane in the reaction between benzenethiol and a 
substituted phenyl benzyl selenoxide.  They were unable to obtain any structural evidence 
for this species, but did observe, via ESI-MS, a cyclization product that could arise from 
this proposed intermediate.  The authors also acknowledged the possibility of an 
alternative pathway of direct formation of the cyclic product that does not proceed via the 
thioselenurane intermediate.  Very recently, Kumakura et al. proposed the possible 
intermediacy of a thioselenurane in the reaction of trans-3,4-dihydroxyselenoxolane with 
thiols, but were unable to obtain any evidence for formation of this species 34.  Turning to 
Ebselen oxide, Fischer and Dereu 33 first proposed that the reaction between Ebselen 
oxide and benzylmercaptan might proceed via the initial formation of a transient cyclic 
thioselenurane intermediate, whereas a thioseleninate intermediate was observed by 
Kumar et al. in the reaction of Ebselen oxide and benzenethiol using ESI-MS 30.  
However, to our knowledge, actual evidence for the intermediacy of a thioselenurane 




We have previously shown that phenylaminoalkyl selenides react 
stoichiometrically with hydrogen peroxide and peroxynitrite, and that the resulting 
selenoxide products are readily recycled back to the corresponding selenides by cellular 
reductants such as GSH 7-9, 21, 24.  We have further demonstrated that these 
phenylaminoalkyl selenides protect DNA against peroxynitrite-induced damage, and that 
GSH-mediated redox cycling results in enhanced protection of DNA against 
peroxynitrite-induced damage 16.  The results reported here elucidate the chemical nature 
of this redox cycling process, and demonstrate that redox cycling of phenylaminoalkyl 
selenides is an efficient cycle consisting of a rapid two-step process with initial formation 
of a thioselenurane intermediate followed by complete regeneration of the original 
selenide.  This contrasts sharply to the complicated redox cycle of the well-studied 
organoselenium compound, Ebselen, which consists of multiple reaction pathways with 
several intermediates and byproducts 12, 13, 18, 25.  Recent investigations have shown that 
Ebselen is an inefficient catalyst due to deactivating pathways, where unreactive 
intermediates hinder the regeneration of the original compound 18, 40, 49, 50.  Thus, the 
results reported here enhance the attractiveness of phenylaminoalkyl selenides as 
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INVESTIGATIONS INTO THE THERAPEUTIC ANTIOXIDANT 
PROPERTIES OF PHENYLAMINOETHYL SELENIDES AND 
THEIR ENCAPSULATION IN NANOCARRIERS 
 
3.1 Introduction 
 Hydrogen peroxide (H2O2) is the product of superoxide (O2
˙ˉ) degradation via 
superoxide dismutases (SOD) or spontaneous breakdown.  H2O2 originates endogenously 
from a variety of enzymes (i.e.oxidases).  Being a small, stable, molecule capable of 
diffusing through cellular membranes, gives H2O2 the characteristics needed to be a 
highly effective signaling molecule.1-4  At low concentrations, H2O2, is capable of 
inhibiting many proteins through the oxidation of unprotonated cysteine residues and 
Fe+2 cofactors (i.e., phosphatases, caspases, and transcription factors).  Reversible 
oxidation of target molecules via H2O2 has been linked to phosphatase activity, gene 
transcription, epidermal growth factor, and insulin signaling, inflammation, etc.5-9 
Although at low concentrations, H2O2 acts as a signaling molecule, at high 
concentrations this small molecule becomes cytotoxic and is well known to induce DNA 
and cellular membrane damage, eventually leading to apoptosis.10, 11  Furthermore, in the 
presence of metals such as iron and copper, H2O2, is converted to more reactive ROS 
through Fenton chemistry.  The simplest form of the Fenton reaction, in which hydroxyl 
radicals are formed from ferrous iron and H2O2, can be written as a two-step process 
(Equations 1 and 2).  In the literature, there is a continuous debate on whether the product 




“crypto” radical or a ferryl species.4, 12-16 Because of this controversy, there are two 
additional alternatives to step 1 of the Fenton reaction (Equations 1a and b).4, 17  The 
damage created by the overproduction of H2O2  and other ROS, either generated 
secondarily from H2O2 or  created by other cellular processes, is referred to as oxidative 
stress and has been linked to pathologies such as cancers,  cardiovascular disorders, 
hypertension, Alzheimer’s and other related neurodegenerative diseases.9, 18-22 
 
 +		 → 

 +	 +	∙ (1) 

 +	 ↔	
 + 	∙ +					 (2) 
  
 + 		 →	 − 
∙ +			  (1a) 
 + 		 →	
∙ +	 (1b) 
 
 
As mentioned in chapter 1, selenium is an essential trace element involved in 
many aspects of cellular defenses, homeostasis, and cell cycle progression.  Selenium 
serves as a redox center for several classes of enzymes, many of which play critical 
antioxidant roles in carrying out reduction of cellular oxidants and regeneration of 
cellular reductants.  In epidemiological studies, a low concentration of selenium in 
plasma has been identified as a risk factor for many diseases associated with oxidative 
stress.23-28  In response to these findings, many organoselenium compounds have been 
synthesized and several have been shown to possess antioxidant, antihypertensive, and 
anti-cancer properties.29-45   




possess antioxidant and antihypertensive properties. Phenylaminoalkyl selenides are 
readily taken up into cells and have low toxicity in vivo (mice and rats) 34, 36, 38.  
Moreover, the selenoxide products generated from the antioxidant activity of these 
selenides is readily recycled back to the selenide form by cellular reductants such as 
glutathione (GSH).37, 38, 40, 41, 44, 46, 47.  We have also shown that as a consequence of this 
selenium redox cycling, our compounds protect DNA against damage caused by the 
reactive cellular oxidant, peroxynitrite 31. 
Substantial effort has been dedicated to developing “nanomedicines” as methods 
of delivering low molecular weight molecules and macromolecules.  Nanoparticles, 
micelles, dendrimers, liposomes, etc. are examples of nanocomposite materials currently 
being investigated, undergoing preclinical development or used in prescription 
pharmaceutics. 48-52  The utilization of nanomedicines provide a variety of desirable 
advantages, including improved oral bioavailability, increased drug solubility and 
stability, prolonged exposure, targeted delivery, controlled release, and overcoming 
resistance, while limiting unwanted side effects.  For example, Pandey and Khuller 
demonstrated that upon encapsulation into poly(lactic-co-glycolic) acid (PLGA) 
nanoparticles, the oral bioavailability of streptomycin was increased 21-fold compared to 
intramuscular free drug.53  Murthy et al. were able to significantly prolong the 
antipsychotic effect of risperidone, while reducing the extrapryamidal side effects with 
PLGA encapsulation.54   
When choosing a polymer for pharmaceutical applications, it is important to 
investigate both biodegradability and biocompatibility.  Together, these properties allow 




nontoxic products.  FDA approved polymers for drug delivery systems include poly(ε-
caprolactone) (PCL), poly(lactic acid) (PLA), and PLGA.  Upon cell implantation, PLGA 
nanoparticles undergo hydrolysis and enzymatic degradation to biocompatible substances 
(lactic and glycolic acid), making them biodegradable, biocompatible, and non-cytotoxic 
to cells.  Semete et al demonstrated that PLGA nanoparticles have a wide biodistribution, 
with the highest percentage of accumulation being found in the liver, and substantial 
amounts found in the kidney, brain, confirming their ability to cross cellular barriers and 
reach hard-to-target tissues.55-57  Because of these properties, PLGA is the most 
commonly used polymer for drug delivery systems and is currently used in several 
commercially available pharmaceutics.58-62 
 Here we report the utilization of hydrogen peroxide specific peroxalate 
nanoparticles to demonstrate the phenylaminoalkyl selenide redox cycle involving 
hydrogen peroxide and glutathione, a common cellular oxidant and reductant, 
respectively.  We report the ability of both fluorophenylaminoethyl selenide (FPAESe) 
and its N-acetyl derivative (Nac-FPAESe) to decrease lipopolysaccharide (LPS)-induced 
oxidative stress in human embryonic kidney cells (HEK293T).  Lastly, to increase the 
attractiveness of phenylaminoalkyl selenides as therapeutic agents, we report the 
successful encapsulation of Nac-FPAESe in PLGA nanoparticles and have carried out 
preliminary studies investigating the effects of these encapsulated nanoparticles on LPS-





3.2 METHODS AND MATERIALS 
 
 
3.2.1  Cells  All cell types were maintained at 37ºC in humidified air with 5% CO2.  
Human embryonic kidney cells, HEK293T, (ATCC, Manassas, VA) were cultured in 
Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin.  
3.2.2  Peroxalate Nanoparticles  Peroxalate nanoparticles were made as reported by 
Murthy et al.63 Peroxalate esters were provided by the Murthy laboratory (Georgia 
Institute of Technology, Atlanta, Ga).  Peroxalate polymer (20mg) dissolved in 1.5mL 
dichloromethane and perylene dye (1mg) dissolved in 200µL were mixed and added 
slowly to a polyvinyl alcohol solution (5.0% in phosphate buffer pH 7.4, made fresh and 
filtered with a 0.45 µM filter).  The mixture is homogenized (Power Gen 500, Fisher 
Scientific) and sonicated (Branson Sonifier 250) to a fine emulsion.  Evaporation of 
dichloromethane resulted in a nanoparticle suspension.  Peroxalate nanoparticles were 
characterized by dynamic light scattering using a 90X Particle Sizer (Brookhaven 
Instruments Corporation, Holtsville, NY) 
3.2.3  Chemiluminescence Measurements  Peroxalate nanoparticles were diluted in 
sodium phosphate buffer (pH 7.4, 0.1M) to a concentration of 1mg mL-1.  In a 90-well, 
50µL peroxalate nanoparticle solution was added to various concentrations of H2O2 and 
chemiluminescence measurements were taken using a MLX Microplate Luminometer 
(Dynex Technologies, Chantilly, VA).  An endpoint assay with a 10 sec acquisition time 
was used.  Experiments were repeated in triplicate. 
For experiments investigating the effect of phenylaminoalkyl selenide on H2O2, 




40 minutes, 50µL peroxalate nanoparticle solution was added to the reaction mixture with 
mixing, by shaking of the plate, and chemiluminescence measurements were taken.  
Incubation time was decided by incubation of H2O2 (5mM) with FPAESe or Nac-
FPAESe (5mM) for varying amounts of time. Experiments were done in triplicate.   
For experiments demonstrating the phenylaminoalkyl selenide redox cycle, H2O2 
(2.5 µM) was incubated selenide (FPAESe or Nac-FPAESe (2.5 µM)) in a 1:1 molar 
ratio, or with selenide and GSH (2.5 µM) for 40 minutes at room temperature.  peroxalate 
nanoparticle solution was added to the reaction mixture with mixing, by shaking of the 
plate, and chemiluminescence measurements were taken.  Experiments were done in 
triplicate.   
3.2.4  PLGA Nanoparticles  Selenide loaded PLGA nanoparticles were made by 
nanoprecipitation as reported by Barichello et al.64  Selenide and PLGA were dissolved in 
acetone and added drop wise to PBS pH7.4 with magnetic stirring.  Organic solvent is 
removed by rotary evaporation or magnet stirring for approx. 3hr.  Unencapsulated 
selenide compound is removed through washing/ centrifugation cycles using PBS pH 7.4 
as a rinsing solvent.  100µL of final suspension was removed for Scanning Electron 
Microscopy imaging.  Final suspension is frozen and lyophilized to a fluffy powder.  
Empty PLGA nanoparticles were made using the same procedure. 
PLGA nanoparticle loading is measured by autopsy of weighed amount of PLGA 
nanoparticles with acetone and analyzed using liquid-chromatography mass spectrometry 
on a triple quad tandem mass spectrometer (Micromass Quattro LC) coupled with an 
Agilent 1100 binary HPLC pump.  10µL injections were made onto a Phenomenex 




acetonitrile: water, 0.1% trifluoroacteic acid; b) 95:5 acetonitrile: water, 0.1% 
trifluoroacetic acid, 0.250 ml/min flow rate. Gradient was as follows: 20% B ramp to 
100% B in 20 minutes hold at 100% B for 10 minutes, return to 20% B and hold for 10 
minutes.  Mass spectrometer parameters were as follows: capillary voltage, 3.50; cone 
voltage, 20; source block temperature, 100; desolvation temperature, 250. 
3.2.5  Fluorescent Measurements  HEK293T cells were allowed to grow to confluence 
in 24-well black with clear bottom cell culture plates.  Cells were washed with PBS pH 
7.4, incubated with LPS (2µg/mL, 2hr), varying concentrations of selenide (FPAESe or 
Nac-FPAESe, 1hr), and CM-H2DCFDA (20µM, 30 min in dark environment). 
Fluorescence intensity was measured on a SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale CA), using a well-scan top read assay (λex483 and λem 535). 
 For experiments investigating the effect of Nac-FPAESe loaded PLGA 
nanoparticles on LPS-induced oxidative stress, HEK293T cells were pre-incubated on 
24-well black with clear bottom cell culture plates with Nac-FPAESe PLGA 
nanoparticles. After 24hr cells were imaged under microscope to ensure cells were still 
alive, then incubated with LPS (2µg/mL, 2hr) and CM-H2DCFDA (20µM, 30 min in dark 








 Chemiluminescence and fluorescence experiments were conducted to demonstrate 
the phenylaminoalkyl selenide/ selenoxide redox cycle using a common cellular oxidant 
and reductant in vitro and the response of these compounds to LPS-induced oxidative 
stress in human embryonic kidney cells (HEK293T).  “Peroxalate nanoparticles”, a 
chemiluminescent detection system for hydrogen peroxide developed by Murthy and 
coworkers have been shown to be H2O2 specific and have a linear correlation with 
hydrogen peroxide in the micromolar concentration range 63.  Peroxalate nanoparticles 
generate a chemiluminescence response to H2O2 via a three component reaction 
involving H2O2, peroxalate esters and fluorescent dyes.  As illustrated in Figure 3.1, H2O2 
diffuses into the nanoparticles and reacts with the peroxalate ester groups, resulting in a 
highly reactive dioxetanedione.  Through chemically initiated electron-exchange, the 
dioxetanedione excites the encapsulated fluorescent dye, generating a corresponding 
fluorescent response.  
We synthesized peroxalate nanoparticles following the procedure of Lee et al.  
The nanoparticles were found to be spherical, homogenous nanoparticles using a 90X 
Plus Particle Sizer (Brookhaven Instruments Corporation) with a diameter of 234nm and 
polydispersity index (PDI) of 0.187.  Figure 3.2 demonstrates the linear correlation 

















Further chemiluminescence experiments concluded that both 
fluorophenylaminoethyl selenide (FPAESe) and its N-acetyl derivative (Nac-FPAESe) 
generated a decrease in chemiluminescence due to the depletion of H2O2.  In a 90-well 
plate, H2O2 (5 mM) was incubated with varying concentrations of FPAESe or Nac-
FPAESe for 40 minutes.  An incubation time of 40 minutes was determined to an optimal 
incubation time in preliminary studies in which H2O2 and FPAESe or Nac-FPAESe were 
incubated in a 1:1 molar ratio for varying times (data not shown). After incubation, 
peroxalate nanoparticle solution (1 mg/mL, in PBS pH 7.4) was added to the reaction 
mixture with shaking and chemiluminescence measurements taken immediately on a 
MLX Microplate Luminometer (Dynex Technologies). As shown in Figure 3.3, 
incubation of H2O2 with FPAESe or Nac-FPAESe resulted in a linear decrease in 





Figure 3.3.  Effect of phenylaminoalkyl selenides on H2O2 concentration. n=3  
 
 
   These initial results lead to the investigation of the phenylaminoalkyl 
selenide/selenoxide redox cycle using hydrogen peroxide as the oxidant and glutathione 
as the reductant.  H2O2 was incubated alone, with selenide (FPAESe or Nac-FPAESe), or 
with selenide and GSH for 40 minutes, after which peroxalate nanoparticles were added 
to the reaction mixture with shaking and chemiluminescence measurements taken 
immediately. As shown in Figure 3.4, a statistically significant decrease in hydrogen 
peroxide concentration is observed in the reaction mixture containing H2O2 and selenide, 
compared to H2O2 alone.  A second statistically significant decrease is observed in the 
reaction mixture with H2O2, selenide and GSH, compared to that containing H2O2 and 
selenide.  Control reaction mixtures including H2O2 and glutathione, H2O2 and 
selenoxide, etc. were monitored and did not result in a change of H2O2 concentration.  


























indicating that the inclusion of a reductant such as GSH in the reaction mixture allowed 
for the regeneration of the selenide moiety; creating a selenium-based redox cycle and 
therefore resulting in a greater consumption of H2O2 molecules, than observed in the 




Figure 3.4.  Phenylaminoalkyl selenide redox cycle demonstrated through residual H2O2 
concentration. *=p<0.05 with respect to H2O2 group; **=p<0.05 with respect to H2O2 and 
Selenide group, n=3 
 
 
These in vitro results were then followed by the investigation of the reaction 
between fluorophenylaminoethyl selenides and lipopolysaccharide (LPS)-induced 
oxidative stress in cells using a common fluorescent dye commonly used in the detection 
of cellular H2O2.  LPS binds to multiple cellular receptors including lipid binding protein 
and CD14, causing the production of pro-inflammatory cytokines and the stimulation of 
signaling cascades in immune cells, resulting in the production of ROS and creating a 















predominantly by H2O2, but also shown to be oxidized by peroxynitrite, and hydroxyl 
radicals, is commonly used as a cellular probe for oxidative stress.65-69  Human kidney 
embryonic cells (HEK293T) were washed and sequentially incubated with LPS (2 
µg/mL, 2hr), varying concentrations of FPAESe or Nac-FPAESe (1hr) and CM-
H2DCFDA (20µM, 30 minutes in dark environment), and fluorescence measurements 
(485 and 538 excitation and emission) were taken on a SpetraMax M5 microplate reader 
(Molecular Devices).  A statistically significant dose dependent decrease in ROS-
generated fluorescence was observed with increasing selenide (FPAESe and Nac-
FPAESe) concentrations (Figure 3.5); thus, demonstrating the ability of 
phenylaminoalkyl selenides to reduce cellular oxidative stress in mammalian cell culture. 
 
 
























Systems such as micelles, liposomes, nanoparticles, etc. have been investigated 
for the delivery of therapeutic agents.  PLGA nanoparticles are one of the most well-
studied drug delivery technologies, mainly due to the excellent biodegradable and 
biocompatible properties of the PLGA co-block polymer.  We have successfully 
encapsulated N-acetyl fluorophenylaminoethyl selenide in PLGA nanoparticles using the 
commonly used nanoprecipitation technique, and have conducted preliminary studies 
demonstrating the ability of these selenide loaded nanoparticles to decrease LPS-induced 
oxidative stress in HEK293T cells.   
The nanoprecipitation technique entails mixing of PLGA and drug, dissolved in 
organic solvent, to be added to an aqueous layer under stirring.  The organic solvent is 
removed by stirring or rotary evaporization and the resulting nanoparticle suspension is 
washed with fresh aqueous phase and lyophilized to give an airy powder.  The 
hydrophilic nature of the free amine of FPAESe allowed for the diffusion of the drug into 
the aqueous layer during solvent evaporization, reducing the loading of FPAESe; 
therefore, Nac-FPAESe was chosen as the selenide drug of choice for encapsulation 
optimization and nanoparticles experiments.  Conditions resulting is maximum loading 
consisted of a 2:1 selenide: PLGA mass ratio, a 2:1 aqueous: organic phase ratio, and 
solvent removal by magnetic stirring.  Nac-FPAESe-loaded nanoparticles were confirmed 
to be 113nm in diameter, homogenous with a PI of 0.087 by DLS, shown in Figure 3.6.  
Maximum loading was found to be 3% wt/wt upon acidic autopsy and analysis by liquid 






Figure 3.6.  Characterization of Nac-FPAESe-loaded PLGA nanoparticles. A) Dynamic 
light scattering B) Scanning electron micrograph 
 




HEK293T cells were pre-incubated with Nac-FPAESe loaded PLGA 
nanoparticles for 24 hour, incubated with LPS (2ug/mL, 2hr) and H2-DCFDA (20 µM, 30 
minutes, in dark environment).  Cells were washed with PBS pH 7.4 between 
incubations.  As shown in Figure 3.7, Nac-FPAESe nanoparticles exhibited a dose-
dependent decrease of fluorescence response generated from LPS-induced ROS.  Empty 
PLGA nanoparticles did not demonstrate the same pattern, while actually exhibiting an 
increase in response as dosage increased.  These results were obtained in duplicate 
experiments.  The same selenide dose dependent response was observed with both free 
FPAESe and Nac-FPAESe drugs, indicating encapsulation in PLGA nanoparticles has no 
effect on the pharmaceutical, antioxidant characteristics of the drugs.  This is most likely 
explained by the added stress of nanoparticle endocytosis and the lack of stress 
attenuation provided by the selenide drugs.  It is obvious from these preliminary results 
that further studies are needed. 
 
Figure 3.7.  Effect of Nac-FPAESe and Empty PLGA nanoparticles on LPS-induced 






























3.4  FUTURE WORK 
 The purpose of this work was to strengthen the pharmaceutical potential of 
phenylaminoalkyl selenides by demonstrating their ability to decrease ROS concentration 
in vitro and oxidative stress in cells.  We demonstrated that the redox cycle responsible 
for the potent antioxidant property of these compounds works in the presence of the well 
known cellular oxidant H2O2.  Phenylaminoalkyl selenides were demonstrated to 
attenuate LPS-induced oxidative stress in human embryonic cells in a dose-dependent 
manner.  We have encapsulated Nac-FPAESe in PLGA nanoparticles using the 
nanoprecipitation technique and showed initial results for the attenuation of LPS-induced 
cellular oxidative stress in HEK293T cells with these selenide-loaded nanoparticles.   
 There are many techniques of drug encapsulation into nanocarriers, depending on 
the solubility and stability properties of the drug of interest.  There are four main types of 
encapsulation:  nanoprecipitation, emulsification solvent evaporation, emulsification 
solvent diffusion, and double emulsification solvent evaporation.  Nanoprecipitation is a 
common technique used in the encapsulation of PLGA nanoparticles with a low level of 
difficulty, and for these reasons it was chosen as the method of encapsulation.  Although 
the nanoprecipitation method yields the best results with lipophilic drugs, several 
investigators have reported the encapsulation of hydrophilic drugs in PLGA nanoparticles 
using this method.64, 70-72  Future studies investigating different solvents and non-solvents 
in the nanoprecipitation procedure and even the investigation of different methods may 
prove to yield higher encapsulation percentages.  With an increase in selenide 
encapsulation, it is possible that a greater effect of oxidative stress attenuation will be 
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THE ANTIOXIDANT PHENYLAMINOETHYL SELENIDE 
REDUCES DOXORUBICIN-INDUCED CARDIOTOXICITY IN A 
XENOGRAFT MODEL OF HUMAN PROSTATE CANCER 
 
4.1  Introduction 
Anthracyclines are common, highly successful antibiotic chemotherapy agents 
used to treat a variety of cancers including luekemias, lymphomas, breast, uterine, and 
lung cancers.1  Adriamycin, better known as Doxorubicin (DOX), is the most commonly 
prescribed anthracycline in the US (Figure 4.1).  Doxorubicin binds tightly to DNA, 
interrupting many DNA activities.  For instances, the primary mode of doxorubicin 
anticancer activity is the inhibition of topoisomerase II, an enzyme responsible for the 
cleaving of the DNA double helix for the purpose of untangling DNA supercoils in DNA 
replication, segregation of sister chromosomes, and gene transcription.1, 2  Secondary 
modes of activity include DNA intercalation and inhibition of nuclear helicases, the 









The advantages of DOX and other anthracyclines do not come without a cost; as a 
side effect, this class of anticancer agents produces ROS and induces oxidative stress in 
nontargeted tissues, leading to ‘normal tissue injury’.5  Heart, kidney and brain tissues 
have been reported as areas of ‘normal tissue injury’.5  DOX treatment has been shown to 
dysregulate blood pressure and flow as well as decrease heart contractility.6  In addition, 
DOX toxicity has been shown to cause myofibrillar loss, sarcoplasmic reticulum 
disruption, mitochondria and swelling and lesions.7  These characteristics eventually lead 
to cardio-toxicities, such as cardiomyopathy and congestive heart failure.1, 8  While the 
cardiotoxic effect has been known to occur after a single dose of DOX (240mg/m2) and 
as late as seven years after termination of dosing, the cardiotoxicity of DOX has 
consistently been shown to be dose-dependent.9, 10  Current recommendations suggest 
that the total cumulative dose of anthracycline should not exceed 550mg/m2 body surface 
area.1, 8, 11 
There are several proposed mechanisms for anthracycline-mediated cardiotoxicity 
including free radical formation, oxidative damage to membrane lipids and cellular 
components, inhibition of DNA synthesis, release of vasoactive substances such as 
histamine and catecholamine, increased intracellular calcium (Ca2+) concentrations, 
changes in cardiac β-adrenergic receptors, and lower glutathione peroxidase activities in 
the heart.12-14  Among these, the primary cause of myocardial damage has been correlated 
to the formation of free oxygen radicals.15  Supporting this view, Wang et.al. have shown 
the toxic effect of DOX on tumor and normal (bovine aortic endothelial and adult rat 
cardiomyocytes) cells is caused by different pathways.16  Apoptosis in normal cells was 




The heart an organ that is a particularly vulnerable to free radical damage induced 
by DOX for several reasons; i) cardiolipin, a phospholipid in cardiomyocytes, has a high 
affinity for DOX, ii) there are limited antioxidants in the heart, and iii) oxidative 
metabolism is activated highly so that the reaction with free radicals is enhanced.15  DOX 
has a high affinity for the negatively charged phopholipid, cardiolipin, found in the 
mitochondrial inner membrane.  This affinity and the high concentration of 
mitochondrion found in cardiomyocytes, results in a cardiac accumulation of DOX.  
Once accumulated in the mitochondrial membrane, the catalysis of the redox cycling of 
DOX between the quinone and the semiquinone forms, produces high concentrations of 
O2













These oxygen-derived toxic species can be detoxified by antioxidant enzymes such as 
superoxide dismutase, catalase, and selenium-dependent glutathione peroxidase under 
normal physiological conditions. However, DOX metabolism could interrupt this balance 
with high free radical formation and oxidative stress so that lipid peroxidation is induced 
and cellular homeostasis is changed.18, 19  Evidence suggests that DOX treatment reduces 
selenium-dependent glutathione peroxidase in myocardial cells 20, resulting in an increase 
in the formation of free radicals and a decrease in the ability to detoxify them. 
The first incidence of fatal cardiotoxicity from prolonged use of an anthracycline 
was reported in 1967, by Marcez et al.21  Since this discovery, thousands of DOX 
analogues have been synthesized, but none of these are as effective anticancer agents as 
DOX.22  Another approach to mediate anthracycline-induced cardiotoxicity without 
losing the anticancer effectiveness is co-administration with other pharmaceuticals.  
Antioxidants have been shown to be effective against DOX-mediated cardiac toxicity.  
Many studies have examined the ability of antioxidants to protect the heart from DOX-
induced oxidative damage.15, 23  The concomitant administration of antioxidants, e.g., 
vitamin C or α-tocopherol (vitamin E), with DOX has been studied using in vivo model 
systems and accessed clinically.24, 25 
Dexrazoxane is a drug approved by the U.S. Food and Drug Administration 
(FDA) to reduce toxicity associated with extravasation of anthracyclines, and is used to 
reduce anthracycline-mediated cardiotoxicity.  Dexrazoxane is a derivative of EDTA and 
potently chelates iron, thereby interfering with the formation of anthracycline-iron 
mediated free radicals.26  Although dexrazoxane has been shown to reduce anthracycline 




may lead to acute myeloid leukemia and myelodysplastic syndrome.26, 27  Although the 
mechanism responsible for the observed toxicity is not fully understood, it is believed 
that its ability to reversibly antagonize topoisomerase II, leading to direct cytotoxic 
effects or schedule dependent synergistic effects. The FDA and the European Medicines 
Agency has recommended restricting dexrazoxane usage to adult patients with advanced 
or metastatic breast cancer who have received greater than 300 mg/m2 dose of 
doxorubicin or 540 mg/m2 of epirubicin due to concerns over toxicity.27 
Amifostine, another antioxidant drug approved by the FDA, has been shown to 
lessen cisplatin-mediated toxicity on the kidney and salivary glands. Although its 
complete mechanism of action is not known, it is a prodrug that is dephosphorylated in 
tissue by alkaline phosphatase to a pharmacologically active free thiol metabolite.28  This 
metabolite is believed to be a potent scavenger of cisplatin generated free radicals. 
However, in hypertensive rats, amifostine was less cardio protective than dexrazoxane 
and did not prevent doxorubicin weight loss or alter mortality.28 
Other cardiovascular drugs, such as probucol, a lipid lowering drug, are also 
being used to limit cardiotoxicity by decreasing oxidative stress.  Although there are a 
number of compounds that are in clinical use, there is concern related to off-target 
activity and potential interactions with primary chemotherapeutic agents.  
Phenylaminoethyl selenide (PAESe) is a novel antioxidant, developed in the May 
laboratory to treat cardiovascular disease.29-32  PAESe has been shown to exhibit potent 
antioxidant activity, reacting rapidly with many metabolic oxidants such as peroxide, 
peroxynitrite anion, and hydroperoxides.  The selenoxide product generated from this 




readily to the selenide form by cellular reductants such as ascorbate and glutathione, with 
no complex side reactions.19, 29, 33-37  Metabolic oxidants are known to react readily with 
DNA, resulting in base modifications and induction of double- and single-strand 
breaks.19, 38  It has been demonstrated that GSH-mediated redox cycling of PAESe results 
in protection of DNA against oxidant-induced damage.19 
 In collaboration with Dr. Robert Arnold’s research group at the University of 
Georgia, we have investigated the effect of phenylaminoalkyl selenides on cellular 
oxidative stress and anthracycline-induced cardiotoxicity without hindering the desirable 
anticancer properties.  We have shown that PAESe has no effect on the antitumor 
activities of DOX, that free radical accumulation is decreased significantly when DOX or 
tert-buytlhydroperoxide (TBHP), a known oxidant, are codosed with PAESe, and that co-





4.2  METHODS AND MATERIALS 
4.2.1 Materials  PAESe was synthesized, purified and fully characterized as described 
previously [30, 34].  Vincristine was obtained from Calbiochem (La Jolla, CA), and F-
12K Nutrient Mixture (Kaighn’s Mod.) was obtained from Mediatech (Manassas, VA). 
CM-H2DCFDA (5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate 
acetyl ester) was purchased from Invitrogen (Carlsbad, CA).  Doxorubicin hydrochloride, 
tert-butylhydroperoxide (TBHP) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich Inc (St. Louis, 
MO). Acetic acid, dimethyl sulfoxide (DMSO), sulforhodamine B (SRB), trichloroacetic 
acid (TCA), tris(hydroxymethyl)aminomethane (TRIS), Fetal bovine serum and trypsin 
(0.25% w/v) were purchased from Thermo Fisher Scientific Inc. (Rockford, IL).  
4.2.2 Cell lines Androgen-independent human prostate epithelial cells (PC-3) were 
obtained from American Type Culture Collection (ATCC) (Rockville, MD) and were 
cultured in F-12K media supplemented with 10% (v/v) FBS in a humidified cell culture 
chamber (NuAire Inc. Plymouth, MN) at 37˚C, 5% CO2. Cells were passaged when they 
reached approximately 80-90% confluency. 
4.2.3 Cytotoxicity of PAESe  The cytotoxicity of PAESe on PC-3 growth inhibition was 
determined at 24, 48 and 72 h.  PC-3 cells were seeded at 2×103 cells/well in 96 well 
plates with F-12K media supplemented with 10% (v/v) FBS and 100 U/mL of penicillin. 
Plates were incubated for 24 h prior to media change and replacement with serum 
supplemented media containing PAESe (0.1 to 10,000 nM).  Plates were then incubated 
at 37˚C, 5% carbon dioxide for an additional 24, 48 or 72 h.  Three independent studies 




effect was assessed at each time point using a mitochondrial enzymatic assay (MTT) and 
a protein binding assay (SRB), described below. 
4.2.4 Growth inhibition of PAESe and DOX, Vincristine or TBHP  The effect of 
PAESe on the cytotoxic effects of conventional anticancer agents, such as DOX (a 
topoisomerase II antagonist and known to cause free radical mediated cardiotoxicity) and 
vincristine (a tubulin binding drug), and a known oxidant, TBHP, was determined at or 
near their IC50’s.  PC-3 cells were seeded as described above, Cytotoxicity of PAESe.  
Twenty four hours after seeding, the media was withdrawn and replaced with serial 
dilutions of PAESe (100 to 10,000 nM in DMSO) and DOX (100 or 500 nM in DMSO) 
or vincristine (5 to 25 nM in DMSO) or TBHP (3 to 3,000 µM in PBS) to a final volume 
of 200 µL. Three independent studies were performed with 5 replicates for each 
concentration of PAESe. MTT and SRB assays were performed after 24, 48 and 72 h 
incubation time to determine effect on growth.  
The effect of PAESe on the growth inhibition of DOX and TBHP in PC-3 cells 
was also determined under continuous exposure of PAESe.  Serial concentrations of 
PAESe (10 to 10,000 nM) were treated to the PC-3 cells in combination with DOX (100 
to 1,000 nM) or TBHP (3 to 300 µM) 24 h after seeding.  To maintain PAESe 
concentration over study, concentrated PAESe (10 to 10,000 nM) was spiked into each 
well every 24 h after initial drug treatment.  A second independent study was conducted 
where the media was replaced with fresh media and PAESe (10 to 10,000 nM) every 24 h 
(i.e., at 24 and 48 h after initial drug exposure) after initial concomitant treatment to 
provide continuous antioxidant effect.  The growth inhibitory effect was also determined 




4.2.5 Assessment of cell growth and viability The cytotoxic effects of PAESe and/or 
DOX, vincristine, TBHP were tested using conventional MTT and SRB staining. MTT 
and SRB staining were performed as described previously.39, 40  Briefly, 10 µL of MTT 
reagent were added to each well and plates were placed to the same conditions for 2 h.  
The resultant insoluble formazan was dissolved in 200 µL DMSO and absorbance was 
measured at 550 nm using Synergy H/T multi-mode microplate reader (BioTek 
Instruments, Inc., Winooski, VT).  SRB staining was performed by fixing viable cells 
with 10% (w/v) TCA for 1 h at 4˚C.  Fixed cells were stained with SRB dye for 5 min, 
and excess SRB was removed by washing plates with 1% (v/v) acetic acid.  The 
absorbance of cellular protein-bound dye extracted by 10 mM TRIS buffer (pH 7.5) was 
determined at 490 nm using Synergy H/T multi-mode microplate reader.  Mean ± 
standard error of the mean (SEM) was calculated and described as percent (%) of control.  
 4.2.6 ROS Generation  Intracellular formation of ROS was determined by quantifying 
the oxidation of a non-fluorescent marker to its fluorescent product (DCF, 2’,7’-
dichlorofluorescein).  Cell-permanent indicator CM-H2DCFDA is known to detect 
several ROS such as hydrogen peroxide, hydroxyl radical, peroxynitrite anion- and 
peroxyl radical. Briefly, cells (2 x 105) were plated in 96 well plates and incubated for 24 
h in 37˚C at 5% CO2.  CM-H2DCFDA was dissolved in DMSO to make a concentrated 
stock solution and added to each well to final working concentration of 5 µM.  After 
incubating cells at 37˚C for 30 min, the loading media was replaced with pre-warmed 
serum free media, and incubated at 37˚C for 10 min to allow the deacetylation and 
oxidation of the dye. Cells were then treated with different concentration of PAESe (0 to 




in darkness. Cells in the absence of drugs were used as controls.  After 2 h, media was 
aspirated and 0.5% Triton X-100 (pH 7.4) in 0.01 M Tris-HCl (200 µL) was added to 
each wells for 5 min to detach the cells.  Fluorescence intensity of the cell lysates (100 
µL) was measured with a FLUOstar OPTIMA plate reader (BMG Labtech, Offenburg, 
Germany) at an excitation wavelength of 485 nm and an emission wavelength of 520 nm. 
4.2.7 Tumor growth inhibition effect of PAESe  Animal model Nude (NCr) mice 
(body weight, approx. 25 g) at 6-8 weeks of age were obtained from Taconic Farms, Inc., 
(Germantown, NY).  Mice were maintained according to an approved Institutional 
Animal Care and Use Committee protocol at the University of Georgia and the U.S. 
Public Health Service Policy on Humane Care and Use of Laboratory Animals, updated 
1996.  Mice were kept in pathogen-free cages in a light and temperature-controlled 
isolated room and provided with standard rodent chow and sterile water ad libitum during 
the experimental periods.  PC-3 cell suspension in serum free media (1×107 cells/mL) 
was mixed with ice-cold Matrigel (BD Biosciences, Franklin Lakes, NJ) in 1:1 (v/v), and 
100 µL of the mixture was injected subcutaneously into the flank of nude mice to 
establish tumor xenograft.  Tumor growth and body weight were monitored every other 
day.  Tumor volume was assessed using digital calipers as described previously where the 
volume was the product of largest dimension and (smallest dimension)2 × 0.52 41.  When 
tumor volume reached approximately 200 mm3, DOX and PAESe treatment were 
initiated, as described below.  Mice were observed every other day until 1 week after the 
last injection for their general appearance as well as the treatment-mediated toxicities 




4.2.8 Effect of PAESe on antitumor activity of DOX  Mice were divided into four 
treatment groups, control, DOX, PAESe and DOX+PAESe treated, n = 5 to 8 
animals/group. DOX and PAESe were administered weekly by tail vein injections (each 
containing 5 mg/kg DOX and 10 mg/kg PAESe) over four weeks for a total of five 
injections and a total cumulative dose of 25 mg DOX/kg, and 50 mg PAESe/kg.  Control 
animals were injected with the vehicle alone (saline-control) following the same dosing 
schedule.  Two weeks after the last injection, mice were sacrificed by cervical dislocation 
under isoflurane anesthesia.  The heart and tumor were excised rapidly, and stored in 
formalin solution at 4°C until paraffin embedding.  The heart tissues were examined for 
histopathological evidence of cardiotoxicity.  Tumor volume and body weight (mean ± 
SEM) for each group was plotted against time versus and normalized to tumor volume or 
body weight on day 0 (start of treatment).  
4.2.9 Histological Examination For histological evaluation, four hearts from each 
treatment group were fixed in formalin solutions (10%, v/v) for 24 h, bisected 
longitudinally and embedded in paraffin. Serial sections were collected and stained with 
hematoxylin and eosin (H&E).  A total of four sections from each heart were examined 
under a Nikon AZ100 stereo-fluorescent microscope mounted with a Nikon DS-Qi1Mc 
color camera. NIS-Elements image analysis software was used for processing.  
Micrographs were examined microscopically and evaluated for signs of anthracycline-
mediated cardiotoxicity 42 by a pathologist who was initially blinded to their identity. 
4.2.10 Statistical analysis Data from in vitro and in vivo studies were analyzed using 










4.3  RESULTS AND DISCUSSION 
The cytotoxic effects of PAESe on prostate cancer cells (PC-3) were assessed by 
measurement of MTT and SRB absorbance after 24, 48 and 72 h.  MTT and SRB assays 
are colormetric indicators of cell viability that monitor active reductase enzymes and 
cellular protein density, respectively.  As seen in Figure 4.3, PAESe did not inhibit in 
vitro growth significantly at 0.1 to 1,000 nM concentrations, but some growth inhibition 
was observed above 10 µM at 72 h. 
The growth inhibition activity of PAESe in combination with DOX, vincristine 
and TBHP was determined in PC-3 cells.  After 24 h seeding, PAESe and DOX or 
vincristine or TBHP were added into the each well, and then MTT and SRB assays were 
performed after 72 h exposure.  As seen Figure 4.4 A, the cytotoxic activity of vincristine 
on PC-3 cells was not altered by the presence of PAESe, as expected.  TBHP, which is a 
well-known potent oxidizing agent, was used as a positive control to determine the 
antioxidant activity of PAESe.  TBHP exerted oxidative-mediated cytotoxicity on PC-3 
cells when used alone.  However, PAESe significantly (p-value <0.05) decreased this 
cytotoxic effect of TBHP when used in combination in a dose-dependent manner up to 
300 µM, as expected (Figure 4.4B).  In contrast, PAESe had limited effect on DOX’s 
ability to decrease MTT and SRB staining of PC-3 cells when used in combination 
(Figure 4.4C).  The same growth inbition pattersn were observed in continuous exposure 
studies, in which cells were either spiked with PAESe or media was replaced with fresh 
media and PAESe at 24 and 48 h after initial exposure.  Additionally, it was observed that 
this additional exposure did not interfere with the cytotoxic activity of DOX or TBHP in 








    







Figure 4.4. Effect of PAESe on the growth inhibition of vincristine (A), TBHP (B), and 






We next investigated the effect of PAESe on DOX-mediated generation of 
intracellular oxidants using cell-permanent indicator, CM-H2DCFDA to quantify 
production of free radicals.  Preliminary studies suggested that ROS generation was 
maximal at 1 to 2 hours, but not detectable at 24 hours when cells were exposed to TBHP 
and/or PAESe, relative to control (data not shown).  An increase in ROS was observed 
with increasing concentration of both DOX and TBHP, as expected (Table 4.1).  
However, generation of free radicals after exposure to TBHP and DOX was decreased 
significantly (p < 0.05) in the presence of PAESe in a dose-dependent manner. PAESe 
decreased free radicals generated from TBHP and DOX in a dose-dependent manner up 
to 300 µM and 500 nM, respectively. 
 
 
Table 4.1.  Effect of PAESe on THBP and DOX ROS generation 
 TBHP   
 0 µM  30 µM 300 µM 
0 nM 100 121 ± 7 193 ± 13 
100 nM 103 ± 5 111 ± 5 150 ± 10* 
1000 nM 101 ± 3 102 ± 4 142 ± 7* 
 DOX   
 0 nM 100 nM 500 nM 
0 nM 100 142 ± 9 184 ± 11 
50 nM 105 ± 5 118 ± 5* 156 ± 8* 
500 nM 191 ± 2 113 ± 5* 142 ± 9* 






The effect of PAESe on antitumor activity of DOX was determined in an in vivo 
xenograft tumor model of human prostate cancer in NCr nude mice.  Thirty two days 
after initiating treatment, the DOX group (5 mg/kg/week) had significantly smaller tumor 
volumes (223% ± 55) compared to controls (631% ± 204) (Figure 4.5A).  Concomitant 
administration of DOX and PAESe did not significantly alter the antitumor activity of 
DOX (256% ± 65) compared to free DOX (223% ± 55), which agreed with the in vitro 
results. Interestingly, administration of PAESe alone also decreased tumor volume (196% 
± 77) significantly relative to saline treated controls.  There were no significant 
differences in tumor volume of PAESe alone or in combination with DOX relative to 
mice treated with free DOX.  Body weight, a metric of gross systemic toxicity, was 
decreased significantly (p < 0.05) in DOX group (-8.62% ± 4.06) by day 32 (Figure 
4.5B).  Treatment with DOX+PAESe did result in an initial decrease in body weight, 










Figure 4.5.  Effect of PAESe on antitumor activity of DOX in a PC-3 xenograft model monitored by tumor growth volume (A.) and 





Histopathological examination showed evidence of treatment-mediated 
differences between control and treatment groups.  Micrographs of the myocardium of 
the left ventricular wall of control (Figure 4.6 A) and PAESe group (Figure 4.6 C) mice 
showed a histologically normal appearance.  The myocardium was intact with faint 
outlines of cross striation. In contrast, the DOX group (Figure 4.6 B) exhibited evidence 
of treatment-mediated cardiotoxicity using a modification of the Jaenke (1974) method, 
where a slight change in scattered, single myocardial fibers and inflammation is evidence 
of low Grade 1 anthracycline mediated cardiotoxicity.  No evidence of Grade 2 (scattered 
alterations in myocardial fibers throughout the myocardium), Grade 3 (moderate degree 
of change with disseminated myocardial fiber change throughout the section), or Grade 4 
(marked degree of change with most myocardial fibers affected) was observed.  In all of 
the DOX (4/4) treated animals minute inflammatory foci, Grade 1, were observed in each 
longitudinal section.  Further, there was a disruption and fragmentation of the myofibers 
accompanied by a small focus of inflammatory infiltrate composed of small numbers of 
neutrophils and macrophages.  This is a statistically significant difference from the DOX 
+ PAESe group, in which only one of four hearts showed any signs of toxicity.  In the 
DOX+PAESe group (Figure 4.6 D), one minute inflammatory focus was observed, with 
disruption and fragmentation of the myofibers. Overall, alterations in myocardial fibers 
and inflammatory foci were observed in 4/4 of the mice treated with DOX, whereas only 
1/4 treated with DOX+PAESe.  These data suggest that PAESe decreased myocardial 





Figure 4.6.  Micrographs of myocardium sections of control (A), DOX group (B), 






The use of antioxidants may be a favorable approach to reduce the cardiotoxicity 
of anthracyclines, thereby improving clinical utility of these promising chemotherapeutic 
agents.  Many studies have explored the use of antioxidants in diminishing DOX-induced 
cardiotoxicity 15.  A number of FDA approved drugs have been explored as 
chemoprotectants; however, questions remain over their potential to limit 
chemotherapeutic activity or synergistic potential to enhance non-cardiac toxicity.  
PAESe was developed as potent antioxidant to treat cardiovascular disease.  It has 
been shown that selenium redox cycling increases the free radical scavenging effects of 
PAESe against oxidant-induced DNA damage.19  In this redox cycling process, the 
selenoxide-form of PAESe is produced when this selenide reduces cellular oxidants such 
as peroxide or peroxynitrite, and the selenoxide is then recycled back to PAESe by 
cellular reductants such as ascorbate and glutathione.   
Up to 1 µM PAESe was found to have little to no cytotoxic effects to PC-3 cells 
after 72 h exposure.  We then examined whether there would be an effect of PAESe on 
the antitumor activity of DOX.  In this combination study, the range of 100 to 1,000 nM 
DOX were chosen based on the fact that clinically-relevant concentrations (i.e., 1–100 % 
peak plasma concentration) are represented by 10–1000 nM.43  We found that PAESe did 
not affect the antitumor activity with DOX in PC-3 cells at non-toxic or cytotoxic 
concentrations.  The cytotoxicity of DOX has been correlated with antagonism of 
topoisomerase-2 rather than free radical generation, whereas cardiotoxicity has known to 
be more related with free radical formation.44  PAESe did not alter the antitumor activity 
of vincristine, known to inhibit growth via tubulin polymerization.  In contrast, the 




presence of PAESe in a dose-dependent manner up to 300 µM.  These data suggest that 
PAESe may be useful in combination with DOX to preserve DOX’s antitumor activity, 
but decrease the toxicity of its ROS on cardiomyocytes. 
These results were further supported by the effect of PAESe on ROS formation, 
as estimated by CM-H2DCFDA, a membrane permeable non-fluorescent reduced 
derivative of 2,7-dichlorofluorescein.  The acetate groups of CM-H2DCFDA are removed 
by esterase cleavage intracellularly; followed by oxidation that can be determined using a 
fluorescence microplate reader or visualized by fluorescence microscopy. CM-
H2DCFDA can detect several ROS including peroxynitrite, hydrogen peroxide, hydroxyl 
radical, and peroxy radical.  Our results showed clearly that the ROS generation after 
DOX exposure was suppressed significantly in the presence of PAESe. These results 
further support the ability of PAESe to decrease DOX-mediated generation of a variety of 
ROS, without altering its antitumor activity. 
We then examined whether in vitro results in which PAESe decreased ROS 
generation without altering the antitumor effects of DOX could be related to in vivo 
treatment.  In a human prostate xenograft (PC-3) mouse model, concomitant 
administration of PAESe did not alter the antitumor activity of DOX as compared to 
DOX alone.  These results are in agreement with our in vitro data showing PAESe did 
not alter the cytotoxic effect of DOX.  These data also suggest that PAESe was able to 
reverse weight loss associated with continual doxorubicin treatment.  This is in contrast 





It is noteworthy that administration of PAESe alone also had significant antitumor 
effects.  The unexpected anticancer activity of PAESe might be associated with altering 
in vivo immune function.  Antioxidants have been shown to enhance not only the activity 
of several immune cells such as lymphocytes, macrophage and mononuclear cells but 
also the cytotoxicity of natural killer cells, which are known to destroy tumors in a non-
specific fashion.45  Also, immune function has known to be increased by up-regulation of 
the interleukin-2 receptors expression as well as the responsiveness of T cell to 
interleukin-2 through antioxidant activity.  Unlike in vitro studies, tumor cells could be 
more vulnerable to the activity of chemotherapeutic agents in an in vivo system because 
of the immune-enhancing effect of PAESe to increase the cytotoxic activity of a variety 
of immune cells as demonstrated in animal and human studies.45  It should be noted that 
the NCR mice contain a Fox1n1nu mutation that alters immune function, permitting 
implantation of tumor xenografts, but does not render the animal completely devoid of 
immune function.  This is a possible explanation for the increase in antitumor activity of 
PAESe alone, but further studies are needed.   
Histological examinations supported the hypothesis that PAESe can reduce DOX-
mediated cardiotoxicity.  The myocardium of mice treated PAESe alone was intact and 
similar to the control.  Early cardiac damage such as disrupted myocardial fibers, immune 
cell infiltration, and inflammation 42, 46 were observed in all sections after DOX treatment 
and only observed in one tissue section of an animal treated concomitantly with DOX 
with PAESe.  
In conclusion, we have successfully demonstrated that PAESe exhibited in vivo 




Further, concomitant administration of PAESe did not alter DOX antitumor activity, but 
did limit DOX-mediated cardiotoxicity and decreased DOX-mediated weight loss.  These 
effects are believed to be related to its potent antioxidant activity, as assessed by in vitro 
growth inhibition assays, alteration in ROS generation, in vivo tumor growth inhibition 
and histopathological examination.  The benefits of this study are worthwhile because 
this is the first to demonstrate the ability of PAESe to reduce DOX-induced 
cardiotoxicity and weight loss, without altering its antitumor activity, suggesting that 





4.4 FUTURE WORK 
 
 The effectiveness of anthracyclines and the lack of positive results from synthetic 
analogues have sparked interest in other methods of anthracycline-induced cardiotoxicity 
mediation.  One method, the co-administration of an antioxidant supplement 
pharmaceutical has been discussed in previous sections.  The encapsulation of 
anthracyclines into nanocarriers is a second approach to mediate cardiotoxicity and has 
been shown in preclinical trials to be effective in attenuating anthracycline-induced-
toxicity with as effective or greater antitumor activity. 
 Liposomes generally extravasate in areas where capillaries are disrupted and in 
organs lined with fenestrated endothelial barriers and without tight junctions (e.g. liver, 
spleen, and bone marrow).  Because of this behavior, DOX- liposomal formulations 
would be expected to be directed away from the myocardium, which is supplied by 
vessels with tight junctions.  This solution is problematic; liposomes are susceptible to 
rapid clearance by phagocytic cells of the reticuloendothelial system, possibly reducing 
the amount of DOX placed in the tumor. 
 It has been reported that a polyethylene glycol layer applied to liposomes causes 
the impairment of uptake by the reticuloendothelial system and mononuclear phagocyte 
system; therefore, increasing liposomal serum and plasma half-lives.  Compared to 
conventional administration in which DOX enters tissues as a concentrated pulse, 
pegylated DOX liposomes cause DOX to be slowly released over days, and change the 
biodistribution to be primarily cancer cells.  This results in the portion of bioavailable 
DOX at the tumor site at any one time is several times higher than in normal tissues.  As 




while still maintain the highly desirable antitumor activity.  Papahadjopoulos et al. 
reported peak drug levels measured in heart muscle were lower for pegylated liposomal 
DOX than for traditional DOX.47   For example, in preclinical studies, Working et al. 
report when comparing myocardium damage in dogs treated with conventional DOX or 
pegylated liposomal DOX up to a cumulative dose of 10 mg/kg, dogs receiving the 
conventional DOX showed vacuolization and myofibrillar loss in the myocardium while 
dogs receiving the pegylated liposomal formulation showed no histological evidence of 
cardiotoxicity either 1 or 5 weeks after treatment.48  In a clinical trial, patients treated 
with pegylated liposomal DOX for AIDS-related Kaposi’s sarcoma had lower biopsy 
scores compared to those of conventional DOX (0.3 compared to 3.0) despite receiving 
higher cumulative doses of drug.49 
 Some liposomal anthracycline formulations are currently used in clinic, including 
liposomal daunorubicin (DaunoXome®), liposomal doxorubicin (Myocet®, D-99), and 
pegylated liposomal DOX (Doxil® and Caelyx®).  While the encapsulation of the drug 
alone has been shown to reduce cardiotoxicity, there is still room for improvement.  It is 
possible that the combination of the two methods of cardiotoxicity mediation would 
result in the desired decrease in toxicity.  The encapsulation of both antitumor drug and 
antioxidant in the same formulation may be a promising solution.  
 Our laboratory in collaboration with the Arnold laboratory (University of 
Georgia, Athens Ga) have been working on encapsulating phenylaminoalkyl selenides in 
pegylated liposomal formulations used as a nanocarrier for DOX.  This continuation of 
this research and the investigation of the co-encapsulation could possibly demonstrate the 




anthracycline-induced cardiotoxicity and could possibly demonstrate the further 
reduction of cardiotoxicity by combining pegylated liposomal encapsulation as well as 
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CIBER:  CENTER FOR INNOVATIVE BIOMATERIAL EDUCATION 
AND RESEARCH   
 
5.1  Introduction 
 
CIBER, The Center for Innovative Biomaterial Education and Research, is a 
multidisciplinary program focused on developing biomaterials from renewable resources 
and educating the public, scientists and engineers on the needs, opportunities, benefits, 
and issues surrounding biomass conversion.  Two main goals were set for the CIBER 
project: 1) The use of chemical and enzymatic polymerizations to create monomers and 
polymers from compounds originating from cellulose, lignin, and other biomass sources. 
Lipases and other enzymes were investigated to create novel monomers and 
biodegradable polymers. 2) The construction of a website to serve as an outreach tool 
educating students, teachers and the general public on the benefits of investing in 
biodegradable products, and their sources.  This website would also be used as a resource 
for scientist in the field. 
The field of creating usable materials from biomass sources is a large and steadily 
growing area of research.  Today, biomaterials, defined as a material made solely from 
natural or a combination of natural and chemical components, is used in many industries; 
a few examples are, medical device, pharmaceutical, carpeting, automotive, plastics and 
energy.  Biodegradable polymers, are polymers that are broken down by the action of 
living organisms, and constitute a large part of the biomaterial field.  Conventional, 




temperatures, toxic reactants and solvents, and low yields.  Compared to chemical 
catalysis, enzymes allow reactions to be carried out under mild reaction conditions, 
provide high selectivity for substrates and reaction modes, eliminate problematic 
byproducts and are highly effective. 
Enzymes have entered the field of organic synthetic chemistry as powerful 
catalysts for stereo- and regioselective reactions and allowing a strategy for synthesis or 
polymers, some of which are difficult to produce.  The elimination of harsh reaction 
environments and of the need for toxic chemicals has made enzymatic polymerization an 
attractive way to achieve “green chemistry’.  Lipases, enzymes that catalyze the 
hydrolysis of fatty acids, are commonly used as polymerization catalyst.  Lipases have 
been shown to be stable in organic solvents and perform a broad spectrum of reactions, 
including etherification, transesterification, condensation, and Michael addition reactions. 
  Candida Antarctica Lipase B (CALB) (Figure 5.1), due to its broad range of 
substrates and its ability to form different types of bonds, is one of the most common 
enzymes chosen for polymerization.1-5  First crystallized in 1994, CALB is a 33kDa 
lipase with 3 disulphide bonds.6  The catalytic triad, Ser105, His224, and Asp187 lie at 
the bottom of the catalytic pocket.  Two parallel channels lead from the active site serine 
out to the surface of the molecule.  These channels are known as the large, nonselective 
acyl pocket and the smaller alcohol pocket, responsible for the stereoselectivity of the 
enzyme.7  Being one of the few lipases that accept secondary alcohols preferentially, it 
has been used in research and industry for the synthesis monomers and biodegradable 
polymers.8-15  We have been using molecular modeling to investigate the stereoselectivity 















5.2 METHODS AND MATERIALS 
 
5.2.1  Molecular Docking  Simulations were run using Molecular Operating 
Environment (MOE) software, Chemical Computing Group, Inc. (Montreal, Canada).  
Ligands were constructed using MOE builder module.  Polar hydrogens were added to 
the ligands and were minimized using the Engh-Huber force field with default parameters 
and ‘solvation’ embedded.   The receptor used for molecular docking was the CALB 
crystal structure reported by Uppenberg et al.7 (PDB ID 1LBS).   
5.2.2  CALB catalyzed Michael Additions  Michael addition reactions were carried out 
in bulk, with solvents.  To a round bottom flask containing thiol or dithiol and 
acrylonitrile (1:2 molar ratio), 60mg CALB beads (Novozyme 435) were added.  CALB 
beads were vacuum dried for 24hr prior to use. Reaction mixtures were allowed to 
reaction at temperatures 25-60°C, with mixing by shaking at 200 rpm for 48 to 96 hr.  
Reactions were quenched by removal of enzyme beads and diluted with methanol, 






5.3  RESULTS 
 
5.3.1 Molecular Modeling Results 
Chiral secondary alcohols are building blocks in the preparation of natural 
products, chemicals and pharmaceuticals.  Enzymatic resolution with lipases has become 
one of the more common methods for preparation of enantiomerically pure alcohols.  
CALB has been shown to have a high natural enantioselectivity towards secondary 
alcohols.  Adam et al. 16 reported that CALB exhibited the best results out of several 
lipases for the kinetic resolution of α-hydroxy valeric acid. The (S)-enantiomer was 
shown to be the preferred, having an enantiomeric excess of 80% at 55% conversion, 
while the (R)-enantiomer was left unreacted with an enantiomeric excess of 99%. The 
authors reported results from kinetic analysis, but neglected to give any structural reason 
for the difference between the preferred (S)-enantiomer and the unreactive (R)-
enantiomer.  
Using literature and modeling data, sought to better understand the 
enantiospecificity of Candida antarctica Lipase B (CALB) for secondary alcohols and 
other small molecule substrates.  Modeling software, Molecular Operating Environment 
(MOE), was used to model the binding of different enantiomers of CALB substrates in 
the enzyme’s active site.  Substrates were built individually, energy minimized and 
docked into an energy-minimized structure derived from the crystal structure shown in 
Figure 14.7  The results from the docking simulation were ranked by a combination of 1) 
the sum of Gaussians over all ligand atom-receptor atom pairs and ligand atom-alpha 




specific types, and 3) an estimated self-energy of the ligand. The lowest value of this 
combination was taken as the best conformation.   
The preferred (S)- and the unreactive (R)-enantiomers of 2-hydroxy valeric acid 
were docked individually in the CALB active site using MOE. The best result from each 
docking was then superimposed in the active site of CALB in order to visualize any 
differences when binding.  As shown in Figure 5.2A, the (R)-enantiomer is centered in 
the active site, while the (S)-enantiomer is positioned more to the right, closer to the 
catalytic residues of the active site.  As shown in Figure 5.2B, the (S)-enantiomer binds in 
an orientation in which the carbonyl carbon is closer to the catalytic residue, Serine 105, 
than the (R)-enantiomer.  Uppenberg et al.7 pointed out the importance of the epsilon 
amine of histidine 224 in the catalysis of the hydrolysis reaction by CALB.  The alcohol 
oxygen of the substrate must be able to receive a proton from the nitrogen of the enzyme.  
When examining at the interactions between the enantiomers and the catalytic residues of 
the active site, it is noticeable that the (S)-enantiomer is closer to the histidine, with a 
distance of 3.91 Å between oxygen of the alcohol and the hydrogen of the histidine 
(Figure 5.3).  The oxygen of the (R)-enantiomer is further from the histidine with 5.20Å 
between the two atoms (Data not shown).  When considering this important interaction 






Figure 5.2.  (R)- and (S)-2-hydroxy valeric acid in the active site of CALB. Color scheme CALB: blue- Nitrogen, red- Oxygen, large 
grey - Carbon, small grey- Hydrogen; A. (R) and (S)-2-hydroxy valeric acid: red- Oxygen, white- Hydrogen, (R)- green- Carbon, (S)- 
purple- Carbon. A. CALB spacefill with (R)- and (S)-enantiomers in stick form.  B. CALB catalytic triad with both enantiomers 







Figure 5.3.  Distances of hydrogen bonds detected by MOE between the bound (S)-2-
hydroxy valeric acid and the CALB active site. The distance from the epsilon amine of 
His224 to the alcohol oxygen of the α-hydroxy acid is 3.91Å. The color scheme is the 






5.3.2 CALB catalyzed Michael Adduct Monomers 
We successfully used CALB as a catalyst to synthesize, via Michael addition 
reactions, novel compounds that can further be used as monomers in polymerization 
reactions via enzymatic and non-enzymatic catalyzed reactions. Primary and secondary 
amines and thiols were used as nucleophiles.  The Michael addition reaction is a common 
reaction in synthetic organic chemistry between a nucleophile and an α,β-unsaturated 
carbonyl compound. Recently, the reaction has been employed by polymer chemists for 
the synthesis of linear, graft, hyperbranched, dendritic, and network polymers.17  Usually 
these reactions are catalyzed by strong bases, causing unwanted side reactions with 
starting materials and products.  In the base-catalyzed Michael addition mechanism 
(Figure 5.4), the Michael acceptor is first deprotonated by the base resulting in a 
carbanion.  The nucleophile then reacts and proton extraction by the enolate leads to the 
final Michael adduct.  Common catalysts for Michael additions in organic chemistry are 
transition metals and lanthanides.18 
 
 




An alternative to base catalysis is the use of enzymes (Figure 5.5).  The oxyanion 
hole of the lipase active site stabilizes the negative charge of the transition state and the 
His-Asp pair acts as a proton shuttle in the enzymatic mechanism.  The carbonyl oxygen 
of the α,β-unsaturated carbonyl compound is bound in the oxyanion hole formed by 
Gln106, Ser105, and Thr40.  His224 acts as a general base to activate the nucleophile.19  
 
 
Figure 5.5.  Enzymatic catalysis of the Michael addition reaction. 
 
Experimental data has shown that CALB is able to catalyze several Michael 




Amines and thiols have been shown to be good nucleophiles for lipase catalyzed Michael 
additions.20  In a one pot reaction, CALB (Novozyme435, vacuum 24hr) was used to 
catalyze the Michael addition of 1, 2-ethanedithiol and acrylonitrile (1:2 molar ratio) 
resulting in the thioether-nitrile mono- and di-Michael adducts.  Reactions were quenched 
by removal of enzyme beads and analyzed by GC-MS.  Control reactions in which no 
enzyme beads were added did not demonstrate the presence of mono or di-Micheal 
adducts.  After the enzyme catalyzed Michael addition, the nitrile group can easily be 
converted to the free acid through acid hydrolysis and can be further polymerized, 
chemically or enzymatically, using a variety of monomers resulting in a novel polymer 
containing thioether functional groups within the backbone. The free sulfide of the mono-
Michael adduct can be used as a nucleophile in further polymerizations. 
Amines were also used as nucleophiles for CALB catalyzed Michael additions. In 
a one pot reaction, CALB (87mg) catalyzed Michael addition of methylmethacrylate and 
N-phenylethane-1,2-diamine (1:1 molar ratio, rm temp, 24hr) resulted in the propoanoate.  
This product was only observed in the reaction in which CALB enzyme beads were 
present.  Once again, this product is an acceptable monomer for polymerizations having a 
reactive carboxylic acid group.   
 
5.3.3  CIBER Website 
To fulfill an educational objective of the CIBER, a website has been created to 
provide general and scientific information on biomass sources, biomaterials, polymers, 





Figure 5.6.  Introduction page of the CIBER website 
 
ages and education levels on the importance, uses, and sources of biomaterials.  It 
includes a searchable database of literature and presentations in the field of biomaterials, 
a glossary of commonly used definitions and formulas, and a page with activities and 
projects for K-12 students, the website is designed to useful to teachers, students, the 
general public and scientists in the field.  General information is provided through topic 
and subtopic pages on enzyme commonly used in enzymatic polymerizations, 
biodegradable polymers, biomass sources, etc.  A searchable database of scientific peer-
reviewed article summaries provides a more in depth information for those in the field of 
biomaterials or for students conducting literature reviews or research.  An example 
summary can be seen in Figure 5.7.  Presentations given by graduate students and 






Figure 5.7.  Example of literature summary found on CIBER website.21 
 
A Teacher’s Resource page has been added in order to provide teachers of all  
levels (K-12) with an easily accessible compilation of websites containing numerous 
activities, lesson plans, and laboratory experiments for use in teaching biomaterials and 
biomass sources and conversion. The websites included in this list are reputable sources 
of facts and information on the topics and include the U.S. Dept. of Energy and the 
Energy Information Administration. Linked to this page is a list of downloadable PDFs of 


















The CIBER website is constantly being updated and is serving as a tool to introduce the 
area of biomass conversion and the major problems that still remain to be solved by 
researchers in this area. As seen in Figure 5.6, from May 2009 to October 2009 the site 
was being used by an average of 243 different users each month and was generating an 
average of 26,865 hits per month.  Navigations to the website have been referred by 
search engines such as Google, Yahoo and Bing.  
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